Novo Nordisk is planning a major India launch of its blockbuster weight-loss drug Wegovy, aiming for Rs 8,600 crore in sales within 5–7 years. The company eyes top spot in prescription drug sales with ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

As a mass rollout of weight loss injections begins across the NHS, with GPs able to prescribe Mounjaro for the first time ...

WEIGHT loss jabs may also help ward off dementia, a new study suggests. Researchers found that semaglutide – the active ...

Mounjaro has been approved for both type 2 diabetes and weight loss; however, access will be limited by strict eligibility ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

Novo Nordisk has ended its collaboration with Hims & Hers Health for its Wegovy weight-loss blockbuster treatment roughly a month after it began over concerns about what it said was illegal mass ...

Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term ...

Novo Nordisk has ended its collaboration with Hims & Hers Health for its Wegovy weight-loss blockbuster treatment roughly a month after it began over concerns about what it said was illegal mass ...

With weight-loss injections like Semaglutide gaining popularity, experts warn they’re not a one-size-fits-all fix. We got in touch with an expert who explains why long-term success lies in combining ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.